Literature DB >> 8647062

Symptomatology and growth in infants with cow's milk protein intolerance using two different whey-protein hydrolysate based formulas in a Primary Health Care setting.

J J Verwimp1, J G Bindels, M Barents, H S Heymans.   

Abstract

Both growth and the course of allergic symptoms were evaluated in 79 infants with cow's milk protein intolerance, aged three months or younger, diagnosed by standard elimination/provocation and treated with a whey-hydrolysate based infant formula: Nutrilon Pept or Pepti Junior. The efficacy of both products, in terms of symptomatology and growth, was compared with each other. The products differ in fat source (Pepti Junior 50% of its fat as MCT, Nutrilon Pepti normal LCT fat blend) and the presence of lactose (Pepti Junior: lactose free; Nutrilon Pepti: 40% of its carbohydrate as lactose). The study was part of a large project that aimed at standardising the approach towards cow's milk protein intolerance in Baby Health Clinics. Nearly 50 Baby Health Clinics participated in this project. In this study, growth and symptomatology (skin, respiratory tract, gastrointestinal tract) were monitored during an intervention period of at least 10 weeks. Infants in both feeding groups showed normal growth, and in at least 80% of the infants an improvement of the overall symptomatology could be seen during the intervention period. Most profound were the decreases in prevalence and severity of eczema and infantile colic. No differences in efficacy were found in this study between the two infant formulas. It was concluded that the exclusive use of either whey hydrolysate based infant formula resulted in an improvement of allergic symptoms and in normal growth in infants diagnosed by elimination/provocation for cow's milk protein intolerance in a Primary Health Care setting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8647062

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  5 in total

Review 1.  Efficacy of screening immune system function in at-risk newborns.

Authors:  Christopher J Pavlovski
Journal:  Australas Med J       Date:  2014-07-31

Review 2.  Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids.

Authors:  Roman Schiffner; Julia Schiffner-Rohe; Michael Landthaler; Wilhelm Stolz
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study.

Authors:  M Abrahamse-Berkeveld; M Alles; E Franke-Beckmann; K Helm; R Knecht; R Köllges; B Sandner; J Knol; K Ben Amor; A Bufe
Journal:  J Nutr Sci       Date:  2016-10-28

Review 4.  Medium chain triglycerides (MCT) formulas in paediatric and allergological practice.

Authors:  Ewa Łoś-Rycharska; Zuzanna Kieraszewicz; Mieczysława Czerwionka-Szaflarska
Journal:  Prz Gastroenterol       Date:  2016-07-20

5.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.